@article {37960,
	title = {Association of PON1, APOE and SDF-1 Gene Polymorphisms with Treatment Response to Intravitreal Anti-VEGF Treatment in Patients with Retinal Vein Occlusion},
	journal = {Semin.Ophthalmol.},
	year = {2023},
	note = {IS - 1744-5205 (Electronic)
IS - 0882-0538 (Linking)
LA - eng
PT - Journal Article
SB - IM},
	month = {2023/11/24/},
	pages = {1 - 8},
	abstract = {PURPOSE: The purpose of this study was to determine whether specific genetic polymorphisms affect the response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment in patients with macular oedema secondary to retinal vein occlusion (RVO). METHODS: Participants in this prospective study were 50 patients with macular oedema secondary to RVO, who were treated with intravitreal ranibizumab or aflibercept, and were followed-up for 12 months after initiation of treatment. Five single nucleotide polymorphisms (SNPs) from three different genes (APOE, PON1, SDF-1) were examined as potential predictors for treatment response to intravitreal anti-VEGF agents. RESULTS: Patients with the LL genotype of the PON1 L55M SNP had significantly higher reduction in central subfield thickness (CST) at month 12 after initiation of intravitreal anti-VEGF treatment (101.63 +/- 56.80 mum in LL vs. 72.44 +/- 39.41 mum in LM vs. 40.25 +/- 19.33 mum in MM, p = .026). Patients with the M allele of the PON1 L55M SNP were significantly associated with lower reduction in CST compared to non-carriers (68.29 +/- 38.77 mum in LM + MM vs. 101.63 +/- 56.80 mum in LL, p = .032). CONCLUSION: PON1 L55M SNP may serve as a promising genetic biomarker for predicting response to intravitreal anti-VEGF treatment in patients with macular oedema due to RVO},
	url = {PM:37997789},
	author = {Ragkousis,A. and Kazantzis,D. and Georgalas,I. and Theodossiadis, P and Kroupis, C. and Chatziralli, I}
}
